FX-322 in Adults With Acquired Sensorineural Hearing Loss
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, single-dose,
multicenter study to evaluate the efficacy of FX-322, administered by intratympanic
injection, in adults with acquired sensorineural hearing loss (SNHL).